Tissue Labs

TissueLabs is a Swiss-based company specializing in bioprinting technology and biomaterials for tissue engineering and regenerative medicine applications. The company offers two primary bioprinting systems: TissueStart and TissueRay. TissueStart, launched in 2020, is an extrusion-based system that uses technologies such as Extrusion bioprinting, Liquid deposition, Liquid Additive Manufacturing, Paste deposition, and Gel Dispensing Printing to produce elastomers, bio/organic, and edible parts using liquid feedstock. It features a build volume of 125 × 80 × 80 mm and includes a proprietary Mixtrusor system capable of combining different bioinks for complex 3D tissue creation. TissueRay, introduced in late 2021, is the market's first masked stereolithography (MSLA) 3D bioprinter, offering high-resolution printing with a 4K screen and 35 μm dot pitch. It can print as fast as one second per layer, depending on the material, and has a 193 cm3 build volume.

In addition to bioprinters, TissueLabs produces biomaterials for use with their systems and for conventional 3D cell culture experiments. Their product line includes generic biomaterials like alginate, GelMA, and pluronics, as well as tissue-specific hydrogels called MatriXpec for 15 different tissues. These hydrogels are designed to mimic the biological cues of native extracellular matrices, providing tissue-specific microenvironments for 3D cell culture. TissueLabs' technology has been applied in various research areas, including the development of self-oxygenating materials for microtissue fabrication, cartilage tissue for tendinosis studies, mini-intestines for nutrient absorption and colorectal cancer research, and in vitro alveoli microenvironments for lung cancer studies. In January 2023, TissueLabs secured USD 800,000 in funding to accelerate its research and development initiatives, enhance its proprietary technology platforms, expand its team, and establish strategic partnerships within the biotechnology sector.